• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sanofi - Articles and news items

EU approval for Sanofi’s type 2 diabetes treatment

Industry news / 19 January 2017 / Niamh Marriott, Digital Editor

Suliqua is an innovative new combination therapy that has the potential to address significant unmet needs for people living with type 2 diabetes in Europe

Sanofi’s insulin injection Soliqua 100/33 now available in US

Industry news / 4 January 2017 / Niamh Louise Marriott, Digital Editor

It is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide…

Sanofi Pasteur and MSD end joint vaccines business in Europe

Industry news / 3 January 2017 / Niamh Louise Marriott, Digital Editor

Sanofi and its vaccines business unit Sanofi Pasteur will end their vaccine joint-venture with MSD (known as Merck in the US and Canada) – SPMSD…

application

EMA to review Sanofi and Regeneron’s dermatitis drug application

Industry news / 13 December 2016 / Niamh Louise Marriott, Digital Editor

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. The investigational biologic therapy Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) […]

FDA approval for Sanofi’s Soliqua to treat type 2 Diabetes

Industry news / 29 November 2016 / Niamh Louise Marriott, Digital Editor

Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program…

study

Sanofi and Regeneron’s rheumatoid arthritis drug shows superior results

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab…

Antibiotic-resistant ‘superbug’ bacteria found at NHS-funded factories

Industry news / 19 October 2016 / Niamh Louise Marriott, Digital Content Producer

Out of 34 sites tested, 16 were found to be harbouring bacteria resistant to antibiotics, according to the report. Resistance to three major antibiotics…

Success for Regeneron and Sanofi’s atopic dermatitis trial

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

Two placebo-controlled Phase 3 trials, evaluating dupixent in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD)…

Success for Sanofi and Regeneron’s LDL cholesterol trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The trial showed adding praluent to existing therapy reduced LDL cholesterol by approximately 50% from baseline, compared to 2% increase for placebo…

Sanofi sends half a million dengue vaccines to high risk Brazilians

Industry news / 15 August 2016 / Sanofi

Results of the study affirm the vaccine’s consistent efficacy in reducing dengue in two-thirds of the study participants, aged 9 and older. It also documents the ability of the vaccine to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in this age group during the 25 month follow-up phase of the studies…

cimzia arthritis x-ray hands bones

Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

Industry news / 1 August 2016 / Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis…

Stem cell nano drug delivery applications to treat diabetes

Sanofi receives FDA approval of Adlyxin TM for treatment of adults with Type 2 Diabetes

Industry news / 28 July 2016 / Sanofi

U.S. Food and Drug Administration (FDA) have approved Sanofi’s Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringFIND OUT MORE
+ +